Literature DB >> 21912277

A case study for calculating employer costs for lost productive time in episodic migraine and chronic migraine: results of the American Migraine Prevalence and Prevention Study.

Walter F Stewart1, Christa Bruce, Aubrey Manack, Dawn C Buse, Sepideh F Varon, Richard B Lipton.   

Abstract

OBJECTIVE: To model workplace lost productive time (LPT) from episodic migraine (EM) and chronic migraine (CM).
METHODS: We used published estimates of migraine epidemiology and related LPT to model the impact of migraine on two typical US workforce scenarios that differ by gender and age.
RESULTS: In a simulated service sector workforce of 10,000 individuals, the migraine-related LPT was $2.9 million annually compared with $2.1 million for a manufacturing workforce. Individuals with moderate frequency EM accounted for 42% of the cost. Individuals with high frequency EM and CM comprised 10% of all migraine sufferers and accounted for 22% of the LPT.
CONCLUSIONS: Lost productive time impact of migraine and other health problems depends on workforce demographics and the cost of labor. Employers can often estimate LPT costs to reveal priorities for optimizing use of health care.

Entities:  

Mesh:

Year:  2011        PMID: 21912277     DOI: 10.1097/JOM.0b013e31822cff3c

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  5 in total

1.  Workplace Indirect Cost Impacts of Nasal and Sinus Symptoms and Related Conditions.

Authors:  Jordan R Kuiper; Annemarie G Hirsch; Karen Bandeen-Roche; Agnes S Sundaresan; Bruce K Tan; Robert C Kern; Robert P Schleimer; Brian S Schwartz
Journal:  J Occup Environ Med       Date:  2019-08       Impact factor: 2.162

2.  When Mom Has Migraine: An Observational Study of the Impact of Parental Migraine on Adolescent Children.

Authors:  Elizabeth K Seng; Emily D Mauser; Maya Marzouk; Zarine S Patel; Noah Rosen; Dawn C Buse
Journal:  Headache       Date:  2018-10-31       Impact factor: 5.887

3.  Double-Binding Botulinum Molecule with Reduced Muscle Paralysis: Evaluation in In Vitro and In Vivo Models of Migraine.

Authors:  Anna P Andreou; Charlotte Leese; Rosaria Greco; Chiara Demartini; Eve Corrie; Deniz Simsek; Anna Zanaboni; Ksenia Koroleva; Joseph O Lloyd; Giorgio Lambru; Ciara Doran; Oleg Gafurov; Elizabeth Seward; Rashid Giniatullin; Cristina Tassorelli; Bazbek Davletov
Journal:  Neurotherapeutics       Date:  2020-11-17       Impact factor: 7.620

4.  Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K.

Authors:  Modar Khalil; Hassan W Zafar; Victoria Quarshie; Fayyaz Ahmed
Journal:  J Headache Pain       Date:  2014-09-01       Impact factor: 7.277

Review 5.  Effectiveness and Safety of Acupuncture for Migraine: An Overview of Systematic Reviews.

Authors:  Yu-Xi Li; Xi-Li Xiao; Dong-Ling Zhong; Liao-Jun Luo; Han Yang; Jun Zhou; Ming-Xing He; Li-Hong Shi; Juan Li; Hui Zheng; Rong-Jiang Jin
Journal:  Pain Res Manag       Date:  2020-03-23       Impact factor: 3.037

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.